Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Does arginine enhance galactose oxidative capacity in classic galactosemia?
2014-002674-36Phase 2Terminated
- Start
- Sep 2017
- Modality
- Small Molecules, Recombinant Proteins and Enzymes, Peptides
- Countries
- 1
01
Overview
Phase 2, single-arm trial of arginine in Classical Galactosemia (CG). Primary endpoint: Galactose oxidative capacity. Started Sep 2017; status: terminated.
02
Drugs
arginine
03
Conditions
Classical Galactosemia (CG)
Beyond the preview
Go deeper on 2014-002674-36.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2014-002674-36.